Bonus BioGroup Ltd. (BBIXF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 29.79 Million ILS | -11.55% |
| 2022 | 33.68 Million ILS | -44.46% |
| 2021 | 60.63 Million ILS | 239.99% |
| 2020 | 17.83 Million ILS | -14.7% |
| 2019 | 20.9 Million ILS | 13.33% |
| 2018 | 18.45 Million ILS | -1.8% |
| 2017 | 18.78 Million ILS | 26.75% |
| 2016 | 14.82 Million ILS | 18.65% |
| 2015 | 12.49 Million ILS | 26.8% |
| 2014 | 9.85 Million ILS | 7.79% |
| 2013 | 9.14 Million ILS | 6.17% |
| 2012 | 8.61 Million ILS | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 7.21 Million ILS | -12.4% |
| 2024 Q1 | 8.23 Million ILS | 112.44% |
| 2023 Q1 | 8.18 Million ILS | 24.54% |
| 2023 Q4 | 3.87 Million ILS | -48.3% |
| 2023 Q3 | 7.49 Million ILS | 2.94% |
| 2023 FY | 29.82 Million ILS | -11.46% |
| 2023 Q2 | 7.28 Million ILS | -11.07% |
| 2022 Q3 | 8.26 Million ILS | -10.69% |
| 2022 Q1 | 9.57 Million ILS | 74.99% |
| 2022 Q2 | 9.25 Million ILS | -3.34% |
| 2022 FY | 33.68 Million ILS | -44.46% |
| 2022 Q4 | 6.57 Million ILS | -20.5% |
| 2021 Q3 | 10.37 Million ILS | 29.25% |
| 2021 Q4 | 5.47 Million ILS | -47.24% |
| 2021 FY | 60.63 Million ILS | 239.99% |
| 2021 Q1 | 36.76 Million ILS | 750.97% |
| 2021 Q2 | 8.02 Million ILS | -78.16% |
| 2020 Q2 | 4.15 Million ILS | -17.74% |
| 2020 Q1 | 5.05 Million ILS | 10.36% |
| 2020 Q3 | 4.3 Million ILS | 3.71% |
| 2020 FY | 17.83 Million ILS | -14.7% |
| 2020 Q4 | 4.32 Million ILS | 0.26% |
| 2019 Q3 | 4.56 Million ILS | 8.18% |
| 2019 Q1 | 7.55 Million ILS | 49.43% |
| 2019 FY | 20.9 Million ILS | 13.33% |
| 2019 Q4 | 4.57 Million ILS | 0.35% |
| 2019 Q2 | 4.21 Million ILS | -44.2% |
| 2018 Q1 | 5.02 Million ILS | 114.96% |
| 2018 Q4 | 5.05 Million ILS | 14.7% |
| 2018 FY | 18.45 Million ILS | -1.8% |
| 2018 Q3 | 4.4 Million ILS | 11.37% |
| 2018 Q2 | 3.95 Million ILS | -21.28% |
| 2017 FY | 18.78 Million ILS | 26.75% |
| 2017 Q3 | 9.35 Million ILS | 160.84% |
| 2017 Q2 | 3.58 Million ILS | 2.02% |
| 2017 Q4 | 2.33 Million ILS | -74.99% |
| 2017 Q1 | 3.51 Million ILS | 63.37% |
| 2016 Q1 | 3.17 Million ILS | -27.69% |
| 2016 FY | 14.82 Million ILS | 18.65% |
| 2016 Q2 | 3.18 Million ILS | 0.19% |
| 2016 Q4 | 2.15 Million ILS | -65.92% |
| 2016 Q3 | 6.31 Million ILS | 98.21% |
| 2015 Q3 | 3.48 Million ILS | 19.08% |
| 2015 Q2 | 2.92 Million ILS | 12.59% |
| 2015 Q1 | 2.59 Million ILS | -9.86% |
| 2015 FY | 12.49 Million ILS | 26.8% |
| 2015 Q4 | 4.39 Million ILS | 26.22% |
| 2014 Q2 | 2.95 Million ILS | -7.23% |
| 2014 FY | 9.85 Million ILS | 7.79% |
| 2014 Q1 | 3.18 Million ILS | -2.09% |
| 2014 Q3 | 2.16 Million ILS | -26.66% |
| 2014 Q4 | 2.88 Million ILS | 33.07% |
| 2013 FY | 9.14 Million ILS | 6.17% |
| 2013 Q1 | 2.1 Million ILS | 0.0% |
| 2013 Q2 | 1.86 Million ILS | -11.5% |
| 2013 Q3 | 2.45 Million ILS | 31.99% |
| 2013 Q4 | 3.25 Million ILS | 32.17% |
| 2012 FY | 8.61 Million ILS | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -2130.74% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 20.039% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -7546.971% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1235.947% |
| Qrons Inc. | 643.67 Thousand USD | -4528.098% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3125.737% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -0.802% |
| BioStem Technologies, Inc. | 22.97 Million USD | -29.664% |
| Skye Bioscience, Inc. | 13.54 Million USD | -119.892% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -7070.037% |
| Rebus Holdings, Inc. | 664 Thousand USD | -4386.446% |
| CSL Limited | 3.44 Billion USD | 99.136% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 48.137% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -174.133% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -86.068% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -490.832% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 65.674% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -505.745% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -11282.132% |
| SQZ Biotechnologies Company | 85.61 Million USD | 65.206% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -921.523% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1883.489% |
| Mesoblast Limited | 5.9 Million USD | -404.744% |
| Marizyme, Inc. | 19.23 Million USD | -54.835% |
| Genus plc | 147.7 Million USD | 79.831% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -239.323% |
| Pharming Group N.V. | 225.49 Million USD | 86.789% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1354.089% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2120.574% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -257.237% |
| ContraFect Corporation | 56.88 Million USD | 47.635% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -575.714% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1914.537% |
| IMV Inc. | 37.7 Million USD | 21.001% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -967.605% |
| MultiCell Technologies, Inc. | 567.42 USD | -5249979.306% |
| ONE Bio Corp. | 6.44 Million USD | -362.298% |
| Accustem Sciences Inc. | 3.74 Million USD | -695.159% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 65.338% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -5500.024% |
| Q BioMed Inc. | 3.43 Million USD | -766.838% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -20.534% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -1033.768% |
| Biomind Labs Inc. | 994.18 Thousand USD | -2896.433% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 70.009% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1592.923% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -343.435% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1497.859% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 119260.0% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1523.349% |
| GB Sciences, Inc. | 1.42 Million USD | -1997.136% |
| Alpha Cognition Inc. | 9.7 Million USD | -206.936% |
| HST Global, Inc. | 140.9 Thousand USD | -21041.604% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -2548.212% |
| Halberd Corporation | 74.84 Thousand USD | -39703.853% |
| Enzolytics Inc. | 2.17 Million USD | -1266.823% |
| Agentix Corp. | 1.37 Million USD | -2071.669% |
| Resverlogix Corp. | 12.71 Million USD | -134.346% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -716.006% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 98.057% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -2753.448% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -1138.703% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1786.213% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -774.895% |
| AVAX Technologies, Inc. | 7.31 Million USD | -307.509% |
| Zenith Capital Corp. | 8.94 Million USD | -233.11% |
| Genscript Biotech Corporation | 825.34 Million USD | 96.391% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -170900.517% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -1113.285% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -17269.351% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1450.831% |
| Kadimastem Ltd | 2.41 Million USD | -1136.042% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1410.623% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -16314.58% |
| LadRx Corporation | 3.81 Million USD | -681.522% |
| Cell Source, Inc. | 4.32 Million USD | -588.731% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3125.737% |
| NovAccess Global Inc. | 2.46 Million USD | -1107.657% |
| Affymax, Inc. | 39.38 Million USD | 24.364% |
| Itoco Inc. | 919.14 Thousand USD | -3141.063% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -602.857% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -2562.198% |
| Mobile Lads Corp. | 554.54 Thousand USD | -5271.962% |
| CytoDyn Inc. | 18.05 Million USD | -64.968% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -118259.887% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -13436.11% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1998.195% |
| SYBLEU INC | 160.87 Thousand USD | -18417.367% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1540.129% |
| International Stem Cell Corporation | 5.27 Million USD | -465.168% |
| Bioxytran, Inc. | 3.82 Million USD | -679.813% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -56489.795% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -146338.578% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 17.857% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1741.162% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -3948.462% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -857.57% |
| Neutra Corp. | 243.82 Thousand USD | -12117.98% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -70.648% |
| PureTech Health plc | 144.59 Million USD | 79.398% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -45.389% |
| IXICO plc | 4.7 Million USD | -532.887% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -238.638% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 74.7% |
| CSL Limited | 3.89 Billion USD | 99.235% |
| Cellectis S.A. | 97.32 Million USD | 69.39% |